TherapeuticsMD Q2 EPS $(0.24) Misses $(0.07) Estimate, Sales from Cont Ops $400.00K Miss $500.00K Estimate

8/14/23 6:58:47 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $TXMD alert in real time by email

TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.07) by 242.86 percent. This is a 93.02 percent increase over losses of $(3.44) per share from the same period last year. The company reported quarterly sales of $400.00 thousand which missed the analyst consensus estimate of $500.00 thousand by 20.00 percent.

Get the next $TXMD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TXMD

Date	Price Target	Rating	Analyst
3/11/2022	$3.00 → $2.50	Buy	HC Wainwright & Co.
11/12/2021	$4.00 → $3.00	Buy	HC Wainwright & Co.

More analyst ratings

$TXMD
Press Releases

Fastest customizable press release news feed in the world

TherapeuticsMD Announces Third Quarter 2024 Financial Results
TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(567) thousand, or $(0.05) per basic and diluted common share, compared to a net loss of $(1.4) million, or $(0.13) per basic and diluted common share, for the third quarter of 2023. License and Service Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $547 thousand for the third quarter of 2024, a
11/12/24 4:05:00 PM ET
$TXMD
Biotechnology: Pharmaceutical Preparations
Health Care
TherapeuticsMD Announces Second Quarter 2024 Financial Results
TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(1.05) million, or $(0.09) per basic and diluted common share, compared to a net loss of $(2.4) million, or $(0.24) per basic and diluted common share, for the second quarter of 2023. License and Service Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $234 thousand for the second quarter of 2024, a
8/12/24 4:05:00 PM ET
$TXMD
Biotechnology: Pharmaceutical Preparations
Health Care
TherapeuticsMD Announces First Quarter 2024 Financial Results
TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(0.8) million, or $(0.07) per basic and diluted common share, compared to net loss from continuing operations of $(2.3) million, or $(0.24) per basic and diluted common share, for 2023. License and Service Revenues from Continuing Operations Gross license royalties totaled approximately $1.2 million under the Mayne License Agreement for the three months en
5/10/24 4:05:00 PM ET
$TXMD
Biotechnology: Pharmaceutical Preparations
Health Care

$TXMD
Leadership Updates

Live Leadership Updates

TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers
- Robust Strategic Alternatives Process Continues - TherapeuticsMD, Inc. (NASDAQ:TXMD), ("TherapeuticsMD" or the "Company") an innovative, leading women's healthcare company, announced today the appointment of Dr. Brian Bernick and Mr. Mark Glickman as the Company's Interim Co-Chief Executive Officers and Co-Principal Executive Officers. Dr. Bernick and Mr. Glickman succeed Mr. Hugh O'Dowd as the Company's Chief Executive Officer. Prior to this appointment, Dr. Bernick, the Company's co-founder, served as Chief Scientific and Medical Officer, and Mr. Glickman served as Chief Business Officer. The Company also announced that the Board of Directors appointed The Honorable Tommy Thompson, w
9/12/22 6:50:00 AM ET
$TXMD
Biotechnology: Pharmaceutical Preparations
Health Care
CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors
Pioneer in the field of regenerative medicine who brought four products from concept through FDA approval and market launch CEL-SCI Corporation (NYSE:CVM) today announced the appointment of Dr. Gail K. Naughton to its Board of Directors. Dr. Naughton has been a pioneer in the field of regenerative medicine for over 35 years. She was the founder of Advanced Tissue Sciences (NASDAQ:ATIS) where she oversaw the design and development of the world's first up-scaled manufacturing facility for cell-based products, established corporate development and marketing partnerships with companies including Smith & Nephew, Medtronic, and Inamed Corporation, was pivotal in raising over $350 million from t
8/8/22 8:45:00 AM ET
$CVM
$HSTO
$TXMD
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O'Dowd, as Chief Executive Officer
- Mr. O'Dowd to succeed Robert G. Finizio, effective on or before December 31, 2021 - - Mr. Finizio appointed Vice Chair of the Board - TherapeuticsMD, Inc. (NASDAQ:TXMD) (TXMD or the Company), an innovative, leading women's healthcare company, today announced key leadership changes, including the appointment of Hugh O'Dowd, the Company's current President, as the Company's Chief Executive Officer and member of the board of directors. Mr. O'Dowd will succeed Robert G. Finizio, the Company's Co-founder and current Chief Executive Officer, effective on or before December 31, 2021. Mr. Finizio will continue with the Company and has been appointed Vice Chair of the Board of Directors. "I wan
11/11/21 6:45:00 AM ET
$TXMD
Biotechnology: Pharmaceutical Preparations
Health Care

$TXMD
Market Insights

Live Market Insights

TherapeuticsMD Q1 EPS $(0.07) Up From $(0.24) YoY
TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(0.07) per share. This is a 70.83 percent increase over losses of $(0.24) per share from the same period last year.
5/10/24 4:07:02 PM ET
$TXMD
Biotechnology: Pharmaceutical Preparations
Health Care
5 Value Stocks In The Healthcare Sector
The Meaning Behind Value Stocks A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued. The following stocks are considered to be notable value stocks in the healthcare sector: Organon (NYSE:OGN) - P/E: 4.4 BioNTech (NASDAQ:BNTX) - P/E: 7.47 TherapeuticsMD (NASDAQ:TXMD) - P/E: 0.52 Innoviva (NASDAQ:INVA) - P/E: 6.93 Procaps Gr (NASDAQ:PROC) - P/E: 5.84 Or
3/4/24 9:44:45 AM ET
$BNTX
$INVA
$OGN
$PROC
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Overview Of Value Stocks In The Healthcare Sector
The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock. Below is a list of notable value stocks in the healthcare sector: Quoin Pharmaceuticals (NASDAQ:QNRX) - P/E: 2.43 BioNTech (NASDAQ:BNTX) - P/E: 7.66 Nuwellis (NASDAQ:NUWE) - P/E: 0.02 TherapeuticsMD (NASDAQ:TXMD) - P/E: 0.47 Syros Pharmaceuticals (NASDAQ:SYRS) - P/E: 8.32 Quoin Pharmaceuticals saw an increase in earnings per share from -2.13 in Q2 to $-1.95 now. Most recently, BioNTech reported earnin
2/12/24 9:43:58 AM ET
$BNTX
$NUWE
$QNRX
$SYRS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Medical/Dental Instruments

$TXMD
Financials

Live finance-specific insights

TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma
- Mayne Pharma gains exclusive U.S. commercialization rights for TXMD's products and acquires certain assets - - TXMD received approximately $153.1 million at closing; portion of proceeds used to repay all outstanding indebtedness under Sixth Street facility and redeem all outstanding preferred equity - - TXMD is eligible to receive up to $30.0 million in milestone payments and a minimum of $42.6 million in royalty payments - TherapeuticsMD, Inc. (NASDAQ:TXMD) ("TherapeuticsMD," "TXMD" or the "Company"), an innovative, leading women's healthcare company, today announced that it has completed its previously announced transaction with Mayne Pharma Group Limited ("Mayne Pharma"), an ASX-lis
1/3/23 6:50:00 AM ET
$TXMD
Biotechnology: Pharmaceutical Preparations
Health Care
TherapeuticsMD Announces Third Quarter 2022 Financial Results
- Q3 total revenue of $20.9 million - - ANNOVERA TRx growth of 10% year-over-year - - Reduced operating expenses by $22 million year-over-year - TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, leading women's healthcare company, today reported financial results for the third quarter ended September 30, 2022. "Our products continue to be adopted by healthcare providers and patients, and we continue to believe that they represent a significant opportunity. Our prescriber bases grew, and we added around 1,500 new prescribers for ANNOVERA and around 1,600 for IMVEXXY. Total quarterly prescriptions for both products remained relatively stable compared to the second
11/14/22 4:05:00 PM ET
$TXMD
Biotechnology: Pharmaceutical Preparations
Health Care
TherapeuticsMD Announces Second Quarter 2022 Financial Results
- Quarterly total net revenue of $28.6 million - - ANNOVERA® TRx of 9,329, an increase of 28% over Q2 2021 - - Conference call scheduled for 8:30 a.m. ET today - TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, leading women's healthcare company, today reported financial results for the Second Quarter ended June 30, 2022. "We saw solid revenue growth during the quarter, with an increase of 24% over the prior year period, while also experiencing a 21% decrease in operating expenses. The U.S. Food and Drug Administration's recent approval of our supplemental new drug application for ANNOVERA has significantly enhanced our ability to meet demand for the product.
8/15/22 6:50:00 AM ET
$TXMD
Biotechnology: Pharmaceutical Preparations
Health Care

TherapeuticsMD Q2 EPS $(0.24) Misses $(0.07) Estimate, Sales from Cont Ops $400.00K Miss $500.00K Estimate

Chat with this insight

Recent Analyst Ratings for $TXMD

$TXMD Press Releases

Fastest customizable press release news feed in the world

TherapeuticsMD Announces Third Quarter 2024 Financial Results

TherapeuticsMD Announces Second Quarter 2024 Financial Results

TherapeuticsMD Announces First Quarter 2024 Financial Results

$TXMD Leadership Updates

Live Leadership Updates

TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers

CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors

TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O'Dowd, as Chief Executive Officer

$TXMD Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Collins Cooper C. bought $7,099 worth of shares (4,094 units at $1.73), increasing direct ownership by 9% to 52,016 units (SEC Form 4)

Director Collins Cooper C. bought $2,039 worth of shares (1,200 units at $1.70), increasing direct ownership by 3% to 47,922 units (SEC Form 4)

Walker Marlan D converted options into 70,000 shares and sold $43,684 worth of shares (19,050 units at $2.29), increasing direct ownership by 439% to 62,565 units (SEC Form 4)

$TXMD Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by TherapeuticsMD Inc.

SEC Form SC 13D/A filed by TherapeuticsMD Inc. (Amendment)

SEC Form SC 13D/A filed by TherapeuticsMD Inc. (Amendment)

$TXMD SEC Filings

SEC Form 10-Q filed by TherapeuticsMD Inc.

TherapeuticsMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form DEFA14A filed by TherapeuticsMD Inc.

$TXMD FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for BIJUVA issued to THERAPEUTICSMD INC

FDA Approval for IMVEXXY issued to THERAPEUTICSMD INC

FDA Approval for BIJUVA issued to THERAPEUTICSMD INC

$TXMD Market Insights

Live Market Insights

TherapeuticsMD Q1 EPS $(0.07) Up From $(0.24) YoY

5 Value Stocks In The Healthcare Sector

Overview Of Value Stocks In The Healthcare Sector

$TXMD Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HC Wainwright & Co. reiterated coverage on TherapeuticsMD with a new price target

HC Wainwright & Co. reiterated coverage on TherapeuticsMD with a new price target

$TXMD Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Collins Cooper C. bought $7,099 worth of shares (4,094 units at $1.73), increasing direct ownership by 9% to 52,016 units (SEC Form 4)

Director Collins Cooper C. bought $2,039 worth of shares (1,200 units at $1.70), increasing direct ownership by 3% to 47,922 units (SEC Form 4)

$TXMD Financials

Live finance-specific insights

TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma

TherapeuticsMD Announces Third Quarter 2022 Financial Results

TherapeuticsMD Announces Second Quarter 2022 Financial Results

Recent Analyst Ratings for
$TXMD

$TXMD
Press Releases

$TXMD
Leadership Updates

$TXMD
Insider Trading

$TXMD
Large Ownership Changes

$TXMD
SEC Filings

$TXMD
FDA approvals

$TXMD
Market Insights

$TXMD
Analyst Ratings

$TXMD
Insider Purchases

$TXMD
Financials